On August 6, 2022, the Securities Times Biomedical Innovation Forum and the 2nd Drug Innovation Award Ceremony hosted by the Securities Times were held in Shanghai. Chairman founder of ImmuneOnco，Dr.Tian, Wenzhi,, was successfully selected as the "Top Ten Drug Innovation Scientists in 2021", and Drug candidate IMM2902 for Injection won the "Annual Drug Innovation Pioneering Award".

On July 15, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that the first global CD47×HER2 bispecific molecule (IMM2902) have received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for breast cancer. The grant of FTD by the US FDA is a major affirmation to IMM2902.

On June 29, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that SIRPaFc recombinant protein targeting human CD47 ，IMM01， combined with azacitidine (AZA) in the treatment of relapsed and refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) Phase Ib/II clinical study (clinical research project number: IMM01-02), completed the first patient enrollment for first dosing.

On June 20, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that, on June 20, local time, an FDA-registered Phase I clinical trial of the first globally novel bi-specific antibody-receptor fusion protein targeting human CD47xHER2（IMM2902) completed the first patient in (FPI).

On June 16, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the first bispecific antibody-receptor recombinant protein targeting human CD47 x HER2 (IMM2902), authorized by the United States Patent Office (APPLICATION No.: US 16/535,075).